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Abstract
Objective
To assess the natural history and treatment eﬀect on survival among patients with transthyretin-
associated familial amyloid polyneuropathy (TTR-FAP) stage 1 Val30Met.
Methods
Multi-institutional, hospital-based study of patients with TTR-FAP Val30Met prospectively
followed up until December 2016, grouped into untreated (n = 1,771), liver transplant (LTx)-
treated (n = 957), or tafamidis-treated (n = 432) cohorts. Standardizedmortality ratios, Kaplan-
Meier, and Cox methods were used to estimate excess mortality, survival, and adjusted hazard
ratios (HRs) for all-cause mortality.
Results
Disease-modifying treatments decreased TTR-FAP excess mortality from 10 to 4 (standardized
mortality ratio 3.92, 95% conﬁdence interval [CI] 2.64–5.59). Median overall survival of
untreated and LTx-treated cohorts was 11.61 (95% CI 11.14–11.87) and 24.73 years (95% CI
22.90–27.09), respectively, and was not reached in the tafamidis-treated cohort (maximum
follow-up, 10 years). Both disease-modifying treatments improved survival. Among early-onset
patients (younger than 50 years of age), tafamidis reduced the mortality risk compared with
untreated patients by 91% (HR 0.09, 95% CI 0.03–0.25, p < 0.001) and with LTx-treated
patients by 63% (HR 0.37, 95% CI 0.14–1.00, p = 0.050). Previous tafamidis treatment did not
aﬀect mortality risk after LTx (HR 0.83, 95% CI 0.25–2.78, p = 0.763). Among late-onset
patients (50 years and older), tafamidis reducedmortality risk by 82% compared with untreated
patients (HR 0.18, 95% CI 0.06–0.49, p = 0.001).
Conclusion
LTx and tafamidis convey substantial survival beneﬁts, but TTR-FAP mortality remains higher
than in the general population. These results strongly reinforce the importance of timely
diagnosis and earlier treatment, boosting the pursuit for an increased life expectancy.
Classification of evidence
This study provides Class III evidence that for patients with stage 1 Val30Met TTR-FAP, LTx
and tafamidis increase survival.
MORE ONLINE
Class of Evidence
Criteria for rating
therapeutic and diagnostic
studies
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Transthyretin-associated familial amyloid polyneuropathy
(TTR-FAP) is an autosomal-dominant, adult-onset, progressive
neurodegenerative systemic disease, described in 1952 by Cor-
ino de Andrade.1 TTR-FAP is rare with endemic populations
predominantly in Portugal, Sweden, Japan, and Brazil.2–4 Its
symptoms stem from amyloidosis that results from misfolding
of the TTR protein tetramer.2,5–7 More than 120 TTR gene
mutations are associated with TTR-FAP, the most common of
which is Val30Met.5 If untreated, the disease progresses rapidly
to death, usually within the ﬁrst decade after symptom onset.2,8,9
Orthotopic liver transplantation (LTx) was ﬁrst implemented
in the 1990s as a surgical gene therapy strategy to ameliorate
or halt familial TTR amyloidosis.10,11 In the past decade, the
oral disease-modifying treatment tafamidis became avail-
able as a treatment option at 20 mg once daily, ﬁrst in the
context of clinical trials (2007) and later as an approved drug
(November 2011 in the European Union) for the treatment
of adult patients with early-stage TTR-FAP to delay disease
progression.12,13Other treatment options are being evaluated
in phase 3 trials.14,15
Although disease-modifying treatments are used worldwide to
delay or halt disease progression, challenges in clinical as-
sessment remain because of disease rareness, clinical hetero-
geneity, incomplete natural history, and uncertain treatment
eﬀectiveness. Hence, in this study, we aimed to assess natural
history survival, evaluate the eﬀect of LTx and tafamidis on
survival, explore prognostic factors, and compare treatment
eﬀectiveness in patients with early-onset (younger than 50
years of age) and late-onset (50 years and older) disease.
Methods
The report of this study follows the STROBE (Strengthening
the Reporting of Observational Studies in Epidemiology)
statement.16
Study design and participants
This was a multi-institutional, hospital-based cohort study of
consecutive symptomatic adult patients (18 years and older)
with a diagnosis of TTR-Val30Met FAP given prospective
longitudinal follow-up since the ﬁrst patient observation in
19391 through the end of the study on December 31, 2016, at
either of 2 Portuguese referral centers. Historically, diagnosis
of TTR-Val30Met FAP was based on the patient’s clinical
ﬁndings, family history, and pathology. Since 1985, when
genetic testing became available,17 it was possible to link all
cases to families in whom the Val30Met mutation was con-
ﬁrmed. Asymptomatic carriers were excluded.
To account for selection bias and to reduce clinical hetero-
geneity, we predeﬁned diﬀerent populations for comparative
purposes.
For the tafamidis cohort, we included all patients who started
treatment, regardless of whether they discontinued tafamidis
(intention-to-treat approach), and all those who underwent
subsequent LTx because of patient preference or disease
progression despite tafamidis treatment.
The intended overall LTx cohort for comparative analysis
consisted of patients who underwent transplantation begin-
ning in 1992, the year LTx became a routine treatment option
in Portugal. Although clear-cut absolute and relative contra-
indications for LTx are diﬃcult to establish, the following
factors are considered at Portuguese centers for the selection
of patients: age (younger than 50 years); disease duration (<7
years); low polyneuropathy disability score (stage 1 disease);
modiﬁed body mass index ≥600 kg/m2·g/L; no severe auto-
nomic dysfunction; absence of amyloid cardiomyopathy; and
no signiﬁcant renal dysfunction.18,19
Patients who underwent LTx in 2012 or later were excluded
(in Portugal, tafamidis became a ﬁrst-line treatment option in
2012, and selection to treatment biases could have occurred
because of physician or patient preference), as were patients
who underwent LTx at more advanced stages of the
disease20—stages 2 and 3, for which tafamidis is not approved.
We anticipated that more than 20 years of important changes
could have occurred in the LTx setting and could have in-
creased survival because of improvements in surgical tech-
niques, surgeons’ learning curves, enhancement of adjuvant
pharmacologic treatments (e.g., protocols for lifelong
immunosuppressants), and optimization of patient selection
criteria for LTx (e.g., selection of patients with better prog-
nosis factors).21 Therefore, we tested this hypothesis by
comparing survival between patients who underwent LTx
before 2007 and during or after 2007 (the year tafamidis
became available as a treatment option in a clinical trial
context). If no signiﬁcant diﬀerences were found, the overall
LTx cohort selected for primary comparative analysis
encompassed stage 1 patients who underwent LTx between
1992 and 2011 (20-year time interval) to maximize in-
formative cohort follow-up (up to 25 years). Nonetheless,
even in this scenario, we conducted an exploratory compar-
ative analysis considering only LTx patients who underwent
LTx in 2007 and later to assess the robustness of the ﬁndings.
If signiﬁcant diﬀerences were detected, the primary compar-
ative analysis included only patients who underwent LTx in
more recent years.
Glossary
CI = conﬁdence interval; HR = hazard ratio; LTx = liver transplant; mOS = median overall survival; RMST = restricted mean
survival time; SMR = standardized mortality ratio; TTR-FAP = transthyretin-associated familial amyloid polyneuropathy.
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The overall untreated cohort was evaluated within 3 disease-
onset periods: 1992 onward, 1972–1991 (20-year time in-
terval as for the intended overall LTx cohort), and before
1972. We anticipated survival gains over time, even among
untreated patients, as changes occurred in global health care
services relating to TTR-FAP. However, patients with disease
onset in more recent years who have not received treatment
are more likely to have poorer prognoses (for example,
patients with late-onset disease), not fulﬁlling eligibility cri-
teria for available treatment. Therefore, we selected the
1972–1991 untreated cohort for subsequent analysis, pro-
spectively studied since disease onset (stage 1 patients).
Procedures
Data were extracted from clinical records regarding sex, dates
of birth, disease onset and death, and treatment-related data
(type, date of initiation, and follow-up). Disease onset was
deﬁned as the patient’s age when TTR-FAP symptoms were
ﬁrst noticed by the patient. Data discrepancies were actively
searched by means of database queries and resolved through
revision of the patient chart. With the exception of 4% of the
patients (n = 121), who were censored at the time of their last
visit, date of death was conﬁrmed in the National Health
Service User Registry.
Statistical analysis
Pearson χ2 test was used to compare categorical variables.
Continuous variables were checked for normal distribution
and analyzed accordingly with parametric or nonparametric
tests. The overall eﬀect of TTR-FAP treatment on mortality
was assessed through standardized mortality ratios (SMRs)
calculated for the years 1991 (before treatment availability)
and 2016 (end-of-study year), by sex and age group.22
Survival was estimated using the Kaplan-Meier method. All-
cause mortality was evaluated from disease onset (index event)
except for the analysis of prognostic factors among treated
cohorts, in whom overall survival was evaluated since treatment
initiation to account for the eﬀect of disease duration before
treatment on survival. Patients were monitored until death or
end of study. Administrative censoring of data was performed
for patients who were alive at the end of the study (n = 1,176),
for those enrolled in ongoing clinical trials (n = 34), and for
those lost to follow-up (n = 121). For patients in the tafamidis
cohort, the primary analysis also censored patients who un-
derwent subsequent LTx (n = 44)with censoring starting at the
time of transplantation. Sensitivity analysis was also performed
that encompassed all tafamidis-treated patients and included
survival follow-up of patients enrolled in clinical trials and of
those who underwent subsequent LTx.
Adjusted hazard ratios (HRs) and 95% conﬁdence intervals
(95%CIs) were calculated through Cox regression models, all
of which were stratiﬁed by hospital referral center. Within
each treatment cohort, exploration of prognostic factors for
survival included sex, late-onset status, stage (for LTx only),
and disease duration before treatment, all of which were
explored together in a Cox proportional hazards model ad-
justed for decade of onset as a covariate.
Comparisons of treatment eﬀectiveness were made separately
for populations with early- and late-onset disease according to
a Kaplan-Meier method crediting time before treatment in the
LTx and tafamidis cohorts to the untreated cohort. A Cox
regression model with treatment as a time-varying covariate
was used, with adjustment for age at onset in 5-year categories
and for sex.23,24 The treatment variable used a value of zero
until treatment initiation and a value of one from treatment to
death or censoring. This allowed follow-up before LTx or
tafamidis initiation to be credited to the untreated natural
history cohort. To assess the robustness of the ﬁndings, we
have also compared survival between cohorts using the re-
stricted mean survival time (RMST) as a complementary
summary measure to HR,25 since there is evidence that
treatment-eﬀect measures on the basis of RMST are more
conservative than HRs26 and do not rely on hazards pro-
portionality. RMST-based treatment-eﬀect measures were
calculated taking the time horizon as the minimum of the
largest observed event time among all cohorts.
For the early-onset population, and to address whether pre-
vious treatment with tafamidis modiﬁed survival after LTx, we
conducted an exploratory analysis that compared patients
with and without previous tafamidis treatment. To ensure
similar follow-up, non–tafamidis-treated patients included
only those who underwent LTx from 2007 to 2011. A further
exploratory analysis for the early-onset population was per-
formed, comparing LTx and tafamidis-treated cohorts, and
evaluating mortality risk since treatment initiation (index
event) for a period of 10 years. For the population with late-
onset disease, LTx is not a general treatment option; there-
fore, analysis of treatment eﬀectiveness compared only the
tafamidis and untreated cohorts.
Statistical analysis and graphs were performed using Stata
Statistical Software: Release 15.0 (StataCorp LLC, College
Station, TX). The threshold for statistical signiﬁcance was set
at α = 0.05.
Standard protocol approvals, registrations,
and patient consents
The study protocol was approved by the institutional ethics
board committees (Centro Hospitalar do Porto and Centro
Hospitalar Lisboa Norte) and by the National Data Pro-
tection Committee. Informed consent was obtained from live
participants.
Primary research question
Has disease-modifying treatment (LTx and tafamidis) im-
proved survival among patients with Val30Met TTR-FAP?
This study provides Class III evidence that for patients with
stage 1 Val30Met TTR-FAP, LTx and tafamidis increase
survival. This study is rated Class III because of the potential
of important confounding diﬀerences between groups.
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Data availability
Anonymized data generated during the current study are
available on reasonable request from individuals aﬃliated with
research or health care institutions located in Portugal, as
approved by the National Data Protection Committee. See
data available from Dryad (table 1, doi.org/10.5061/dryad.
3583v22).
Results
Characteristics of the study cohorts
The study included 3,221 symptomatic patients. Sixty-one
patients were excluded because of missing data at disease
onset (n = 57) or date of LTx (n = 4). Our sample for analyses
thus included 3,160 patients: 1,771 in the untreated, 957 in
the LTx-treated, and 432 in the tafamidis-treated cohorts
(data available from Dryad, table 1, doi.org/10.5061/dryad.
3583v22). Median follow-up was 10.25 years in the untreated
cohort, 13.67 years in the LTx cohort, and 5.45 years in the
tafamidis-treated cohort. Overall, 1,853 patients (58%) died.
The mean (SD) age at disease onset was 36.7 (12.2) years and
1,697 patients (53.7%) were male (data available from Dryad,
table 1, doi.org/10.5061/dryad.3583v22). The cohorts did
not diﬀer in sex distribution (p = 0.321). The proportion of
patients with late-onset disease and their median age at dis-
ease onset diﬀered between cohorts (p < 0.0001). Both were
lower in the LTx-treated cohort than in either other cohort, as
expected given that LTx is not routinely recommended for
patients with late-onset disease. Median duration of disease
before treatment was longer among LTx-treated than
tafamidis-treated patients (p < 0.0001), also as expected given
the additional waiting time for LTx (data available from
Dryad, table 1, doi.org/10.5061/dryad.3583v22). Similar
results were found for comparisons between the selected
cohorts used for analysis of comparative treatment eﬀective-
ness (table 1).
Effect of treatment
SMR analysis for year 1991 (before LTx became available)
indicated that untreated patients had a 10-fold (SMR 9.79,
95% CI 6.65–13.90) excess mortality rate than did the general
population. In 2016, patients with TTR-FAP faced a 4-fold
(SMR 3.92, 95% CI 2.64–5.59) excess mortality rate com-
pared with the general population, indicating a decrease of
60% after treatment (LTx or tafamidis) became available. The
excess mortality rate was highest in patients 45 to 54 years of
age than in other age groups and was higher in women than in
men (table 2).
Survival prognostic factors
Untreated cohort (natural history)
The 1972–1991 untreated cohort, which exhibited a median
overall survival (mOS) of 11.61 years (95% CI 11.14–11.87
years), showed the highest survival among all untreated
cohorts (ﬁgure 1). In this cohort, the mortality risk was higher
Table 1 Characteristics of patients with Val30Met TTR-FAP in the selected cohorts
Untreated (year of onset
1972–1991) LTx (year of LTx 1992–2011)a
Tafamidis (year of
treatment initiation
2007–2016)
Early Late Early Late Early Late
Patients, n 755 116 855 32 347 85
Male, % 53.5 47.4 52.7 46.9 51.9 48.2
Age at onset, y
Mean ± SD 32.3 ± 6.4 58.3 ± 6.4 31.6 ± 6.1 53.4 ± 4.3 33.8 ± 6.7 61.6 ± 7.8
Median (IQR) 31 (28–36) 57 (53–63) 31 (27–35) 53 (51–57) 33 (29–38) 60 (55–67)
Disease duration from onset to treatment
initiation, y
Mean ± SD — — 4.1 ± 2.7b 4.0 ± 2.9 2.4 ± 2.0 3.2 ± 2.7
Median (IQR) — — 3.5 (2.3–5.2) 3.0 (2.4–4.8) 2.0
(1.0–3.3)
2.7
(1.6–3.8)
Follow-up from onset, y
Mean ± SD 11.9 ± 4.9 9.4 ± 4.2 14.4 ± 6.2 13.1 ± 4.7 5.9 ± 3.0 6.0 ± 3.6
Median (IQR) 11.4
(8.9–14.4)
8.8
(6.4–11.8)
14.1
(10.0–18.7)
12.8
(9.3–16.3)
5.5
(4.0–7.7)
5.4
(3.8–7.7)
Abbreviations: IQR = interquartile range; LTx = liver transplant; TTR-FAP = transthyretin-associated familial amyloid polyneuropathy.
a LTx-treated cohort, excluding patients in disease stages 2 and 3.
b Among early-onset patients, disease duration was 1.7 years (p < 0.0001) higher in LTx-treated than tafamidis-treated patients.
4 Neurology | Volume , Number  | Month 0, 2018 Neurology.org/N
Copyright ª 2018 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
in men than women (HR 1.20, 95% CI 1.04–1.38, p = 0.011)
and in patients with late-onset (mOS 9.21, 95%CI 8.05–10.80)
than early-onset (mOS 11.86 years, 95% CI 11.43–12.19)
disease (HR 1.98, 95% CI 1.60–2.44, p < 0.0001) (ﬁgure 2A).
Liver transplantation
In the LTx comparison cohort (stage 1 patients, 1992–2011),
mOS since disease onset was 24.73 years (95%CI 22.90–27.09);
mOS following LTx was 20.92 (95% CI 18.43–not estimable).
LTx resulted in early excess mortality following the surgical
procedure; the cumulative mortality rate in the ﬁrst year
after LTx was 14% (95% CI 11%–16%). Patients who un-
derwent LTx in more advanced stages of the disease (stage 2 or
3) experienced higher mortality risk than those in stage 1 (HR
1.58, 95% CI 0.94–2.47, p = 0.091). Among patients in stage 1
treated with LTx, the mortality risk was lower in men than in
women (HR 0.70, 95% CI 0.55–0.89, p = 0.003) and in patients
with shorter disease duration before LTx. For each year LTx was
delayed, the mortality risk increased by 17% (HR 1.17, 95% CI
1.12–1.23, p < 0.0001). We found no diﬀerences between
patients with late-onset and early-onset disease (HR 1.59, 95%
CI 0.90–2.80, p = 0.112; ﬁgure 2B).
Tafamidis
The mOS for the tafamidis-treated cohort was not reached,
though the maximum follow-up was only 10 years. The ob-
served survival rate at 10 years after treatment initiation was
92.9% (95% CI 83.1%–97.2%). Mortality risk was greater
among patients with longer disease duration before tafamidis
treatment. For each year tafamidis treatment was delayed, the
risk of death increased by 39% (HR 1.39, 95% CI 1.05–1.83, p
= 0.022). No diﬀerences were found based on sex (HR 1.29,
95% CI 0.27–6.04, p = 0.749) or late-onset vs early-onset
disease (HR 3.40, 95% CI 0.80–14.51, p = 0.098; ﬁgure 2C).
Comparative treatment effectiveness
Although a lower 1-year cumulative mortality rate and
a higher 10-year survival rate were observed in patients who
underwent LTx during 2007 or later vs those who underwent
LTx before 2007 (10% vs 14% and 85% vs 74%, respectively),
no overall survival diﬀerences were found (HR 0.80, 95% CI
0.51–1.23, p = 0.309). Therefore, in accordance with the
prespeciﬁed criteria, for primary comparative analysis, we
considered the overall LTx cohort encompassing stage 1
patients who underwent LTx between 1992 and 2011. Hence,
Table 2 Standardized mortality ratio for TTR-FAP (years 1991 and 2016)
Age group, y Patients at risk, n
Observed deaths, n/expecteda deaths, n Standardized mortality ratio (95% CIb)
Males Females All Males Females All
1991
18–24 10 0/0.02 0/0 0/0.02 — — —
25–34 197 5/0.33 0/0.04 5/0.37 15.20 (4.94–35.47) — 13.51 (4.39–31.53)
35–44 308 5/0.44 5/0.23 10/0.66 11.45 (3.72–26.72) 21.95 (7.13–51.23) 15.05 (7.22–27.67)
45–54 126 3/0.2 6/0.29 9/0.49 15.25 (3.14–44.56) 20.78 (7.63–45.24) 18.54 (8.48–35.20)
55–64 55 2/0.37 1/0.22 3/0.59 5.38 (0.65–19.42) 4.60 (0.12–25.64) 5.09 (1.05–14.88)
65–74 20 2/0.22 1/0.27 3/0.49 9.04 (1.09–32.66) 3.72 (0.09–20.71) 6.12 (1.26–17.88)
≥75 5 0/0.35 1/0.2 1/0.55 — 5.12 (0.13–28.53) 1.82 (0.05–10.13)
Total 721 17/1.93 14/1.24 31/3.17 8.82 (5.14–14.13) 11.29 (6.17–18.95) 9.79 (6.65–13.90)
2016
18–24 2 0/0.00 — — — — —
25–34 115 0/0.05 1/0.01 1/0.06 — 151.19 (3.83–842.40) 18.00 (0.46–100.27)
35–44 475 2/0.42 0/0.14 2/0.56 4.76 (0.58–17.18) — 3.55 (0.43–2.83)
45–54 388 3/0.77 5/0.38 8/1.14 3.90 (0.80–11.40) 13.30 (4.32–31.03) 6.99 (3.02–13.77)
55–64 163 4/0.64 3/0.38 7/1.02 6.21 (1.69–15.90) 7.97 (1.64–23.29) 6.86 (2.76–14.13)
65–74 87 3/0.96 2/0.39 5/1.35 3.12 (0.64–9.10) 5.16 (0.63–18.65) 3.70 (1.20–8.64)
≥75 47 5/1.78 2/1.75 7/3.53 2.81 (0.91–6.57) 1.14 (0.14–4.13) 1.99 (0.80–4.09)
Total 1,277 17/4.62 13/3.04 30/7.66 3.68 (2.14–5.89) 4.28 (2.28–7.32) 3.92 (2.64–5.59)
Abbreviations: CI = confidence interval; TTR-FAP = transthyretin-associated familial amyloid polyneuropathy.
a Expected deaths that would occur if patients with TTR-FAP were at the same mortality risk as the general Portuguese population (data from INE, Statistics
Portugal), according to sex and age.
b The 95% CIs for standardized mortality ratios were computed under the assumption that occurrence of the events followed a Poisson distribution.
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according to the eligibility criteria (see methods), 871, 887,
and 432 patients in the untreated, LTx-treated, and tafamidis-
treated cohorts, respectively, were included in the evaluation
of comparative treatment eﬀectiveness (table 1).
Early-onset disease
Both treatment cohorts experienced increased survival com-
pared with the untreated 1972–1991 cohort. The 10-year
survival probabilities after TTR-FAP onset were 72% (95%CI
69%–75%), 73% (95% CI 68%–78%), and 96% (95% CI
87%–99%) in the untreated, LTx-treated, and tafamidis-
treated cohorts, respectively. The 20- and 30-year survival
probabilities after disease onset were 7% (95% CI 5%–9%)
and 2% (95% CI 1%–4%) in the untreated cohort, and 56%
(95%CI 50%–61%) and 29% (95%CI 18%–39%) in the LTx-
treated cohort, respectively.
Overall, there was a 75% (HR 0.25, 95% CI 0.22–0.29, p <
0.0001) and a 91% (HR 0.09, 95% CI 0.03–0.25, p < 0.0001)
reduction in mortality risk in the LTx-treated and tafamidis-
treated cohorts, respectively. Survival was higher in the tafamidis-
treated cohort than in the LTx-treated cohort; mortality risk was
reduced by 63% (HR 0.37, 95% CI 0.14–1.00, p = 0.050; ﬁgure
3A). The crossing of the LTx and untreated survival curves is
indicative of nonproportionality in the hazards, and therefore the
reported HR should be thought of as an average over time.
Similar results, in terms of direction of treatment eﬀect (although
of lower magnitude) and statistical signiﬁcance, were obtained
for RMST-based measurements (table 3).
Results of the exploratory analysis considering only the more
recent LTx cohort (2007–2011) were of similar magnitude,
including comparison between the tafamidis- and LTx-treated
cohorts (HR 0.36, 95% CI 0.13–1.02, p = 0.055). Similar
results were obtained when comparing the more recent LTx
cohort with tafamidis since treatment initiation (HR 0.18,
95%CI 0.08–0.40, p< 0.0001). Sensitivity analysis that included
post-LTx and post-clinical trial follow-up data for all patients
initially treated with tafamidis showed an 87% mortality risk
reduction compared with the untreated cohort (HR 0.13, 95%
CI 0.06–0.27, p < 0.0001) and a 50% mortality risk reduction
compared with the LTx cohort (HR 0.50, 95% CI 0.24–1.06,
p = 0.072). When comparing tafamidis-naive LTx patients from
2007 to 2011 (more recent and contemporaneous) with those
who underwent transplantation but previously received tafa-
midis, no diﬀerence in posttransplantation survival rate was
observed (p = 0.763, ﬁgure 4).
Late-onset disease
Given that LTx is not generally recommended for patients
with late-onset disease and that only a small set of patients (n =
32) with late-onset disease underwent LTx, no comparative
analysis was performed for this cohort (mOS since disease
onset, 17.04 years, 95% CI 13.31–19.88). Furthermore, this
LTx-treated subgroup represented a highly selected set of
patients with late-onset disease who still fulﬁlled eligibility
criteria for surgery. The 10-year survival probability after TTR-
FAP onset was 49% (95% CI 39%–58%) and 92% (95% CI
71%–98%) in the untreated and tafamidis-treated cohorts, re-
spectively. Overall, among patients with late-onset disease,
tafamidis treatment (n = 85) was associated with an 82% re-
duction in mortality risk compared with the untreated (n =
116) cohort (HR0.18, 95%CI 0.06–0.49, p= 0.001; ﬁgure 3B).
Discussion
This research of more than 3,200 Portuguese patients repre-
sents the largest cohort study of patients with TTR-FAP to
date. Our ﬁndings reveal that both sexes are aﬀected and
disease onset occurs primarily in young adulthood (28–42
years of age). We found a slight but clinically relevant im-
provement in survival among the untreated cohorts of almost
1 year, probably because of easier access to better medical
care. The reduced survival rate of untreated patients in the era
of LTx probably reﬂects the coexistence of clinical charac-
teristics (such as later disease stage and poor nutritional sta-
tus) and social conditions (such as health illiteracy and low
awareness of disease treatment) that precluded the eligibility
and timely access to LTx.
The main clinical relevant ﬁnding of our study is that the
advent of disease-modifying treatments (in particular LTx)
changed dramatically the long-term prognosis for patients
with TTR-FAP in the past 25 years, from a progressive, dev-
astating, fatal disease to a more chronic condition with treat-
ment leading to delayed disease progression. The beneﬁcial
eﬀect of treatment as a whole onmortality was demonstrated by
the 60% SMR reduction from 1991 to 2016; in 2016, however,
Figure 1 Untreated cohort (natural history) Val30Met TTR-
FAP survival
Kaplan-Meier survival estimates in the Val30Met TTR-FAP untreated cohort
(natural history) according to the era of disease onset. CI = confidence in-
terval; HR = hazard ratio; TTR-FAP = transthyretin-associated familial amy-
loid polyneuropathy.
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mortality rates remain 4-fold greater than in the general pop-
ulation. In our study, the prognosis for treated patients was
poorer for those with longer disease duration before treatment,
which is consistent with the published literature on LTx21,27,28
and with the beneﬁts of earlier tafamidis treatment on neuro-
logic progression and nutritional status.29–31This result strongly
reinforces the need to start treatment (either LTx or tafamidis)
at an early stage of the disease.
Figure 2 Untreated, LTx-treated, and tafamidis-treated Val30Met TTR-FAP survival
Kaplan-Meier survival estimates by sex and age at disease onset (early/late onset) according to Val30Met TTR-FAP cohort: untreated (A), LTx-treated (B), and
tafamidis-treated (C) patients. CI = confidence interval; HR = hazard ratio; LTx = liver transplant; TTR-FAP = transthyretin-associated familial amyloid
polyneuropathy.
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The results from the comparative eﬀectiveness analysis raise
several further ﬁndings for discussion. First, among patients
with early-onset disease, tafamidis treatment may result in
improved overall survival compared with LTx, attributable
perhaps in part to the absence of early operative risks. Caution
is required, however, when interpreting this ﬁnding because
median tafamidis follow-up was relatively short as compared
with LTx median follow-up, and mOS has not yet been
reached. Moreover, within the ﬁrst years after the introduction
of LTx, and in contrast to tafamidis, LTx resulted in higher
mortality rates than no treatment. Although this is an expected
ﬁnding, the proportional hazard assumption of the Cox re-
gression analysis is violated, which means that, with longer
follow-up, treatment eﬀect is likely to change. Nonetheless, the
robustness of this ﬁnding is supported by the similar results
found in the analysis that made use of diﬀerent statistical
methods (RMST), as well as in the exploratory analysis that
included only the more recent LTx cohort (2007–2011). This
Figure 3 Comparative survival estimates in patients with early- and late-onset Val30Met TTR-FAP
Kaplan-Meier survival estimates since
disease onset (with 95% CI) in Val30Met
TTR-FAP selected cohorts with compar-
ative treatment effectiveness among
early-onset (A) and late-onset (B)
patients. CI = confidence interval; HR =
hazard ratio; LTx = liver transplant; TTR-
FAP = transthyretin-associated familial
amyloid polyneuropathy.
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more recent LTx cohort experienced an overall higher survival
rate than the former LTx cohort, was contemporaneous with
the tafamidis-treated cohort, and had comparable follow-up.
Second, among patients with early-onset disease and up to 10
years of follow-up, no diﬀerences in survival were found be-
tween LTx-treated patients who did and those who did not
previously receive tafamidis treatment, though other possible
beneﬁts of tafamidis beyond survival—such as improvement
in nutritional and overall health status13—were not analyzed
in this study.
Third, among patients with late-onset disease, a subgroup
with poorer prognosis and shorter median survival,32,33 and
for whom LTx is not generally recommended,34 tafamidis
treatment resulted in a clinically relevant survival beneﬁt.
From a study of the largest LTx cohort of patients with TTR-
FAP (Familial Amyloidosis Polyneuropathy World Trans-
plant Registry, encompassing 2,171 patients from 81 centers
and 21 countries), researchers retrospectively reported21 a 20-
year survival rate of 55.3%, a noteworthy improvement in
overall survival compared with reports on the natural history
of the disease. In the study, higher modiﬁed body mass index,
early onset of disease (younger than 50 years), shorter disease
duration before LTx, and TTR Val30Met rather than non–
TTR Val30Met mutations were found to be independent,
favorable, signiﬁcant factors for survival. The overall highest
transplantation activity contributing to this registry originates
from Portugal, which contributed more than 45% of the data.
Our research shows that TTR-FAP overall median survival
after LTx is 21 years. Limitations of LTx include waiting times
for a compatible donor organ35 and relevant intraoperative
mortality and postoperative complications as evidenced by
the high cumulative ﬁrst-year mortality rate, which is similar
to what others have found.21One interesting ﬁnding from our
study was the higher mortality risk among LTx-treated
women in comparison to men. Although the overall LTx lit-
erature is supportive of this ﬁnding,36,37 the reasons in
Val30Met TTR-FAP remain unclear. The diﬀerence in mor-
tality risk occurs early after LTx. Therefore, this diﬀerence is
probably attributable to imbalanced unobserved baseline
prognostic factors (including systematic epidemiologic bias
Table 3 Post hoc RMST estimates (with 95% CI) among TTR-FAP Val30Met early- and late-onset patients (20 years since
disease onset)
Early-onset cohorts Late-onset cohorts
Untreated LTx Tafamidis Untreated Tafamidis
Patients, n 755 855 347 116 85
RMST, y (95% CI) 12.57 (12.29–12.85) 15.08 (14.40–15.77) 18.36 (15.95–20.77) 10.35 (9.54–11.16) 14.35 (11.48–17.22)
LED, y (95% CI)
LTx vs untreated 2.51 (1.77–3.25) —
Tafamidis vs untreated 5.79 (3.36–8.21) 4.00 (1.02–6.98)
LTx vs tafamidis −3.28 (−5.78 to −0.77) —
LER, ratio (95% CI)
LTx vs untreated 1.20 (1.14–1.26) —
Tafamidis vs untreated 1.46 (1.28–1.67) 1.39 (1.12–1.72)
LTx vs tafamidis 0.82 (0.72–0.94) —
Abbreviations: CI = confidence interval; LED = life expectancy difference; LER = life expectancy ratio; LTx = liver transplant; RMST = restricted mean survival
time; TTR-FAP = transthyretin-associated familial amyloid polyneuropathy.
Figure 4 LTx (with and without previous tafamidis) Val30-
Met TTR-FAP survival since LTx
Kaplan-Meier survival estimates since LTx according to previous tafamidis
treatment in Val30Met TTR-FAP LTx patients with early-onset stage 1 dis-
ease. CI = confidence interval; HR = hazard ratio; LTx = liver transplant; TTR-
FAP = transthyretin-associated familial amyloid polyneuropathy.
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against women and a poorer metabolic status) and/or higher
rate of early LTx fatal complications.
Previous studies evaluating the survival of patients with TTR-
FAP enrolled either a small number of patients27,28 or lacked
comparison groups.21 Furthermore, some assumptions and
conclusions from previous studies may be questionable, such
as reporting a 100% survival rate at 10 years among LTx-
treated patients by excluding deaths considered not related to
amyloidosis.27
An important limitation of our study is its observational de-
sign. We have attempted to deal with selection bias objectively
by using explicit criteria to deﬁne clinically comparable
cohorts and by adjusting for sex, age at onset, and disease
duration before treatment when modeling. However, because
of the unavailability of data, we were unable to include other
possible determinants of outcomes, such as nutritional status21
and other clinical characteristics.38 In addition, using historical
data for comparison has the disadvantage that cohorts may
diﬀer in unmeasured prognostic factors for survival. In our
study, all patients had Val30Met mutation conferring genetic
homogeneity to the population evaluated. Although this may
be considered a strength of this study, it is also a further limi-
tation, because results are not generalizable to other TTR
mutations and other disease presentations, including sporadic
cases and later-stage disease, which are more common in other
geographies with higher genetic and clinical heterogeneity.32,33
Our ﬁndings suggest that potential improvements may be
made in the prognosis of patients with TTR-FAP and strongly
reinforce the importance of timely diagnosis and early treat-
ment initiation. Treatment with LTx or tafamidis dramatically
changed the clinical course of TTR-FAP. However, these
treatments have not proven to reverse established damage. In
fact, mortality rates remain higher than in the general pop-
ulation, which should stimulate further basic and clinical re-
search, targeting the development of biomarkers of early-stage
and subclinical disease, as well as new disease-speciﬁc drugs.
We report a comprehensive treatment eﬀectiveness study
comparing natural history, LTx, and tafamidis treatment in
patients with TTR-FAP. It is unrealistic to expect that ran-
domized controlled trials will address the questions in-
vestigated here. This evidence can be a valuable source of
eﬀectiveness, particularly in a rare-disease setting, and may
inform regulatory agencies, health technology assessment
bodies, and clinical treatment guidelines and recom-
mendations. Therefore, we suggest setting up properly
designed prospective, clinical registries as longer follow-up
data may facilitate understanding of how clinical practice can
reconcile diﬀerent treatment options, especially as new drugs
emerge from phase 3 clinical trials.39,40
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